UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C., 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

November 17, ~~2011~~2013 Date of Report (Date of earliest event reported)

CELLCYTE GENETICS CORPORATION
(Exact name of registrant as specified in its charter)


Nevada	000-52238	86-1127046
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)


14205 SE 36^th St. Suite 100, Bellevue Washington		98006
(Address of principal executive offices)		(Zip Code)

(425) 519-3755
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 42.~~01 Changes In Registrant's Certifying Accountant.~~03

~~CellCyte~~Creation ~~Genetics Corporation (the “Company”) was notified that the audit practice~~ of ~~BehlerMick~~a ~~PS,~~Direct ~~the~~Financial ~~Company’s~~Obligation ~~independent~~or ~~registered~~an ~~public~~Obligation ~~accounting~~under ~~firm~~an ~~(“BehlerMick”),~~Off-Balance ~~was~~Sheet ~~reorganized~~Arrangement ~~as MartinelliMick PLLC (“MartinelliMick”), following the departure~~ of ~~the~~a former managing partner in December, 2010. As of November 1, 2011, BehlerMick resigned as the independent registered public accounting firm of the Company and, with the approval of the Audit Committee of the Company’s Board of Directors, the new legal entity, MartinelliMick PLLC was engaged as the Company’s independent registered public accounting firm. Registrant

~~During~~On ~~the~~November ~~two years ended December 31~~7, ~~2010~~2013, ~~and from January1, 2011, through~~ the ~~engagement of MartinelliMick as the~~ Company’s ~~independent~~issued ~~registered~~to ~~public~~Doug ~~accounting firm~~Cerretti, ~~neither~~John ~~the~~Fluke ~~Company~~and ~~nor~~Randy ~~anyone~~Lieber on(collectively, ~~its behalf consulted MartinelliMick with respect to any accounting or auditing issues involving~~ the ~~Company. In~~“Note ~~particular,~~Holders”) ~~there~~convertible ~~was~~promissory nonotes ~~discussion~~(collectively ~~with~~ the ~~Company~~“Notes”) ~~regarding~~in the ~~application~~aggregate of ~~accounting principles to a specified transaction~~$466,168.90 (the ~~type~~“Principal ofAmount.”). The ~~audit~~Principal ~~opinion~~Amount ~~that~~includes ~~might~~amounts bepreviously ~~rendered~~loaned onto the ~~financial~~Company ~~statements,~~under orprior ~~any~~promissory ~~matter~~notes, ~~that~~interest ~~was~~accrued ~~either~~on the ~~subject~~promissory ~~of a disagreement~~notes, as ~~described~~well inas ~~Item~~additional ~~304~~amounts ofloaned ~~Regulation~~to ~~S-K~~the ~~(“Regulation~~Company. All ~~S-K”)~~prior ~~promulgated~~promissory bynotes ~~the Securities~~ and ~~Exchange~~accrued ~~Commission~~interest ~~(the~~owed ~~“SEC”),~~to ~~with~~Note ~~MartinelliMick,~~Holders orhave abeen ~~“reportable~~cancelled ~~event”~~and asrolled ~~described~~into inthe ~~Item~~amounts ~~304(a)(1)(v)~~owed ofunder ~~Regulation~~the ~~S-K~~Notes.

~~BehlerMick~~The ~~performed~~Notes ~~audits~~are ofpayable on demand to the ~~Company’s~~Note ~~consolidated~~Holders ~~financial~~and ~~statements~~bear ~~for~~simple ~~the~~interest ~~years~~at ~~ended~~eight ~~December~~percent ~~31,~~(8%) ~~2010~~per annum. Principal and ~~December~~all ~~31,~~accrued ~~2009,~~interest ~~BehlerMick’s~~will ~~reports~~be ~~did~~due ~~not~~and ~~contain~~payable anfive ~~adverse~~(5) ~~opinion~~years orfrom athe ~~disclaimer~~date of ~~opinion~~the ~~and~~Notes. In ~~were~~the ~~not~~event ~~qualified~~the orCompany ~~modified~~defaults ason toany ~~uncertainty~~payment of principal or interest, ~~audit~~then ~~scope~~any Note Holder may, orat ~~accounting~~his ~~principles~~option, ~~except~~without ~~that~~notice, ~~such~~proceed ~~reports~~to onenforce ~~our~~collection ~~financial~~thereof. Notes ~~statements~~are ~~contained~~convertible anat ~~explanatory~~the ~~paragraph~~option ~~with~~of ~~respect~~the toNote ~~uncertainty~~Holders asinto toshares of the Company’s ~~ability~~common tostock ~~continue~~in aslieu of payment of the Principal Amount and all accrued interest at a ~~going~~price ~~concern~~of $0.01 per share.

During the two years ended December 31, 2010, and from January1, 2011, through November 1, 2011, there were no (i) disagreements between the Company and BehlerMick on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to its satisfaction, would have caused BehlerMick to make reference to the subject matter of such disagreements in connection with its report, or (ii) “reportable events,” as described in Item 304(a)(1)(v) of Regulation S-K. SIGNATURES

~~The~~Pursuant ~~Company~~to isthe ~~unable~~requirements toof ~~obtain~~the ~~Exhibit~~Securities ~~4.01~~Exchange ~~from~~Act of 1934, the ~~predecessor~~registrant ~~auditor,~~has asduly ~~the~~caused ~~firm~~this noreport ~~longer~~to ~~practices~~be ~~public~~signed ~~accounting.~~on its behalf by the undersigned hereunto duly authorized.

~~SIGNATURES~~CELLCYTE GENETICS CORPORATION Date: November 7, 2013. _______________________________________ Name: John M. Fluke, Jr. Title: Interim Principal Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CELLCYTE GENETICS CORPORATION Date: November 4, 2011. _______________________________________ Name: John M. Fluke, Jr. Title: Interim Principal Executive Officer

Filing Compare · CELLCYTE GENETICS CORP